Literature DB >> 30170240

Production and characterization of a novel HPV anti-L2 monoclonal antibody panel.

S M Bywaters1, S A Brendle2, J Biryukov3, J W Wang4, J Walston5, J Milici6, R B Roden7, C Meyers8, N D Christensen9.   

Abstract

The major capsid protein of HPV, L1, assembles into pentamers that form a T = 7 icosahedral particle, but the location of the co-assembled minor capsid protein, L2, remains controversial. Several researchers have developed useful monoclonal antibodies targeting L2, but most react with linear epitopes toward the N-terminus. As a means to better define the virus capsid and better assess the localization and exposure of L2 epitopes in the context of assembled HPV, we have developed a panel of 30 monoclonal antibodies (mAbs) which target the N-terminus of L2 amino acids 11-200, previously defined as a broadly protective immunogen. Select mAbs were processed with enzymes and anti-L2 Fabs were generated. These new mAb/Fab probes will be beneficial in future studies to unravel the placement of L2 and to help better define the role of L2 in the HPV lifecycle and the nature of the broadly protective epitopes.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antibody; Epitope; Fab; HPV; L2; Minor capsid protein; mAb

Mesh:

Substances:

Year:  2018        PMID: 30170240      PMCID: PMC6309409          DOI: 10.1016/j.virol.2018.08.017

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  55 in total

1.  Further evidence that papillomavirus capsids exist in two distinct conformations.

Authors:  Hans-Christoph Selinka; Tzenan Giroglou; Thorsten Nowak; Neil D Christensen; Martin Sapp
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

2.  Biosynthesis of human papillomavirus from a continuous cell line upon epithelial differentiation.

Authors:  C Meyers; M G Frattini; J B Hudson; L A Laimins
Journal:  Science       Date:  1992-08-14       Impact factor: 47.728

Review 3.  Progress and prospects for L2-based human papillomavirus vaccines.

Authors:  Rosie T Jiang; Christina Schellenbacher; Bryce Chackerian; Richard B S Roden
Journal:  Expert Rev Vaccines       Date:  2016-03-10       Impact factor: 5.217

4.  Seroepidemiology of Human Papillomavirus 16 (HPV16) L2 and Generation of L2-Specific Human Chimeric Monoclonal Antibodies.

Authors:  Joshua W Wang; Subhashini Jagu; Wai-Hong Wu; Raphael P Viscidi; Anne Macgregor-Das; Jessica M Fogel; Kihyuck Kwak; Sai Daayana; Henry Kitchener; Peter L Stern; Patti E Gravitt; Cornelia L Trimble; Richard B S Roden
Journal:  Clin Vaccine Immunol       Date:  2015-05-13

5.  Linear B-cell epitopes in the N-terminus of L2 of bovine papillomavirus type 4.

Authors:  G Knowles; G J Grindlay; M S Campo; L M Chandrachud; B W O'Neil
Journal:  Res Vet Sci       Date:  1997 May-Jun       Impact factor: 2.534

6.  Preparation and properties of a papillomavirus infectious intermediate and its utility for neutralization studies.

Authors:  Joshua W Wang; Subhashini Jagu; Kihyuck Kwak; Chenguang Wang; Shiwen Peng; Reinhard Kirnbauer; Richard B S Roden
Journal:  Virology       Date:  2013-12-20       Impact factor: 3.616

7.  Monoclonal antibodies recognizing cross-neutralization epitopes in human papillomavirus 16 minor capsid protein L2.

Authors:  Sari Nakao; Seiichiro Mori; Kazunari Kondo; Koji Matsumoto; Hiroyuki Yoshikawa; Tadahito Kanda
Journal:  Virology       Date:  2012-10-07       Impact factor: 3.616

Review 8.  Developments in L2-based human papillomavirus (HPV) vaccines.

Authors:  Christina Schellenbacher; Richard B S Roden; Reinhard Kirnbauer
Journal:  Virus Res       Date:  2016-11-23       Impact factor: 3.303

9.  Two amino acid residues confer type specificity to a neutralizing, conformationally dependent epitope on human papillomavirus type 11.

Authors:  S W Ludmerer; D Benincasa; G E Mark
Journal:  J Virol       Date:  1996-07       Impact factor: 5.103

10.  Mechanisms of human papillomavirus type 16 neutralization by l2 cross-neutralizing and l1 type-specific antibodies.

Authors:  Patricia M Day; Ratish Gambhira; Richard B S Roden; Douglas R Lowy; John T Schiller
Journal:  J Virol       Date:  2008-02-27       Impact factor: 5.103

View more
  2 in total

Review 1.  Immunodiagnosis and Immunotherapeutics Based on Human Papillomavirus for HPV-Induced Cancers.

Authors:  Zhen Dong; Renjian Hu; Yan Du; Li Tan; Lin Li; Juan Du; Longchang Bai; Yingkang Ma; Hongjuan Cui
Journal:  Front Immunol       Date:  2021-01-08       Impact factor: 7.561

Review 2.  Progress in L2-Based Prophylactic Vaccine Development for Protection against Diverse Human Papillomavirus Genotypes and Associated Diseases.

Authors:  Pola Olczak; Richard B S Roden
Journal:  Vaccines (Basel)       Date:  2020-10-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.